AstraZeneca Plots Crucial IDO Phase III Combo Trial With Incyte Post author:Sam Post published:October 30, 2017 Post category:BioPharma Astra and Incyte are pushing forward on the development of immunotherapy combination treatments. Source: BioSpace You Might Also Like Merck Laying Off 50 Employees in North Carolina December 10, 2017 Georgia's Visioneering Technologies Successfully Snags $33.3 Million IPO March 15, 2017 AstraZeneca PLC Hits Milestone With Approval of Potential Bladder Cancer Blockbuster May 1, 2017